Newly approved head and neck cancer treatment improves care for first time in more than 20 years
Pembrolizumab has been approved as a perioperative immunotherapy for locally advanced head and neck squamous cell carcinoma, providing improved outcomes beyond standard care.
This approval introduces the first perioperative immunotherapy for locally advanced head and neck squamous cell carcinoma, offering earlier treatment options and improved outcomes compared with standard care.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability